Botox (onabotulinumtoxinA): J0585 billing, dosing and coverage

Botox and the botulinum toxin family

5 HCPCS codes, 5 distinct molecules, 5 potency assays: Botox is one of five botulinum toxin products on the market. They are not interchangeable, and Botox has no biosimilars; every competitor listed below is a separately branded, separately dosed product. Pricing comparison lives in Current Botox pricing.

What Botox is billed for

Botox carries twelve FDA-labeled indications, each with its own ICD-10 code and its own protocol dose: chronic migraine, cervical dystonia, overactive bladder, adult and pediatric neurogenic detrusor overactivity, adult and pediatric upper and lower limb spasticity, axillary hyperhidrosis, blepharospasm, and strabismus. Full dosing by indication is in Botox dosing by indication below, and the procedure code each one bills is in Botox billing reference.

Dysport (J0586)

Ipsen · abobotulinumtoxinA. Priced and billed in its own dose-unit scale: a Dysport Unit count is not a Botox Unit count, and the two must never be converted against each other.

Xeomin (J0588)

Merz · incobotulinumtoxinA.

Myobloc (J0587)

Supernus · rimabotulinumtoxinB, the only serotype B product in the family; Botox and the other three are serotype A.

Daxxify (J0589)

Revance · daxibotulinumtoxinA-lanm.

Botox dosing by indication

No indication has an induction phase: each one has a fixed protocol dose, repeated no sooner than every 12 weeks once the prior dose's effect has worn off. What varies is the dose itself, the injection sites, and what the label requires documented before the first treatment.

Boxed warning

“Postmarketing reports indicate that the effects of BOTOX and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects” is the FDA label's own language, covering asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties among them. Document the dose, the sites injected, and any post-injection symptoms in the chart at every visit.

Label prerequisites

Two indications are written into the label itself as second-line therapy, not free-standing options: overactive bladder is indicated only after an inadequate response to, or intolerance of, an anticholinergic medication, and axillary hyperhidrosis is indicated only when the sweating has been inadequately managed by topical agents. Document the specific prior agent, and the outcome, before the first Botox claim; the diagnosis code alone does not establish medical necessity for either indication.

Interval and ceiling

• No indication is retreated sooner than 12 weeks after the prior dose (axillary hyperhidrosis commonly runs 16 weeks between treatments).
• Adults must not exceed 400 Units across all indications treated in any rolling 3-month interval, even when two indications are billed the same day.
• Pediatric patients are capped at the lesser of 10 Units/kg or 340 Units across all indications in a 3-month interval.
• The label sets no stopping point for treatment: it continues for as long as the indication persists and the response holds. Loss of response over time is usually neutralizing antibody formation.

Vials and waste, by protocol dose

Botox ships in 100- and 200-Unit single-dose vials, reconstituted with preservative-free saline; nothing is shared or pooled across patients. Because most protocol doses don't divide evenly into those two sizes, waste is the norm rather than the exception; the arithmetic is in Botox billing reference below.

Need the billing units for a patient? Convert dose to J0585 billing units →

Botox billing reference

HCPCS

J0585: 1 Unit per billing unit. Units are the label's own dosing measure; never bill in milligrams.

NDC

Two vial sizes, each its own NDC: 0023-1145-01 (100 Units) and 0023-3921-02 (200 Units). Pad to 11 digits with a leading zero in the appropriate segment for CMS-1500 Box 24A.

The FDA label also lists package-size NDCs 0023-1145-02 and 0023-3921-03 alongside the single-dose vial NDCs above; confirm which package was actually opened before billing. The 50-Unit vial sold as Botox Cosmetic is not a covered benefit and is never billed to a payer.

Administration: site CPT, never 96372

The injection is the procedure, and the CPT follows the site treated, because Botox has no administration code of its own. 96372 is wrong on every Botox claim.

A complete claim has three parts: J0585 × the Units given, J0585-JW × the Units discarded (when any were), and the procedure code for the site treated.

Guidance codes 95873 (electrical stimulation) and 95874 (needle EMG) are billable add-ons only alongside the extremity, trunk, neck and laryngeal codes: 64616, 64617 and 64642–64647. They are not billable with 64615, 64612, 67345, 64650/64653 or 52287.

Vial waste (JW/JZ)

Vials are 100 or 200 Units, single-dose, reconstituted with preservative-free saline. Because most protocol doses don't divide evenly into those two sizes, a JW line is the norm, not the exception.

• Chronic migraine, 155 Units: drawn from one 200-Unit vial (or two 100-Unit vials); 45 Units go on a JW line either way.
• Cervical dystonia, 236 Units (trial median): drawn as a 200-Unit vial plus a 100-Unit vial; 64 Units on JW.
• Upper or lower limb spasticity, 300 Units: drawn as a 200-Unit vial plus a 100-Unit vial; nothing left over, JZ.
• Upper limb spasticity, pediatric, 150 Units: drawn from a 200-Unit vial; 50 Units on JW.
• Blepharospasm, 25 Units: drawn from a 100-Unit vial; 75 Units on JW.
• Strabismus, 5 Units: drawn from a 100-Unit vial; 95 Units on JW, so the waste line exceeds the drug line.
• Overactive bladder, 100 Units: one 100-Unit vial, nothing discarded, so JZ.
• Neurogenic detrusor overactivity, 200 Units: one 200-Unit vial, nothing discarded, so JZ.

Modifiers

JZ: required when no drug is discarded. JW: required for documented waste, and routine for Botox for the reasons above.

Effective July 1, 2023, CMS requires the JZ modifier on all single-dose container claims when no drug is discarded, and JW whenever any is. Document the discarded Units in the chart and bill the JW line on a separate claim line, same date of service, same HCPCS code; never both modifiers on the same line.

Modifier 25: same-day E/M. Append modifier 25 to the same-day E/M code only if a significant, separately identifiable evaluation occurred beyond the routine pre-injection check-in, which is bundled into the procedure code.

TB: 340B drug pricing. Hospitals that acquire onabotulinumtoxinA through 340B and bill Medicare report the TB modifier, the sole 340B identifier since CMS discontinued JG on January 1, 2025.

Claim form

CMS-1500 / 837P (physician office; POS 11) field map for a J0585 claim.

Calculate units & JW/JZ →

Botox coverage

• 22 of 29 commercial payer policy sets require prior authorization
• 0 name a preferred onabotulinumtoxinA product
• 29 payers carry an onabotulinumtoxinA policy, covering 771 individual rules across covered indications, clinical prerequisites, quantity limits, contraindication exclusions, reauthorization, prior authorization, dosing, continuation of therapy, billing and coding, not-covered, site of care, and combination rules
• 24 of 29 payers require another product or step first, most often failure of, or intolerance to, an anticholinergic for the bladder indications, two prophylactic drug classes for chronic migraine, or a topical agent for axillary hyperhidrosis
• 76 rules set a per-indication quantity limit, and 31 more set reauthorization terms that require continued-response documentation to keep the claim approved
• Because Botox, Dysport, Xeomin, Myobloc and Daxxify are five distinct HCPCS codes for five distinct molecules, a payer's “botulinum toxin” policy may authorize one, several or all five under a single policy shell; confirm which HCPCS the policy actually names before treating

ICD-10 codes by indication

Use the most specific code supported by chart documentation. Each labeled indication has its own code.

Medicare carries no National Coverage Determination for botulinum toxins; coverage runs through your MAC's botulinum toxin Local Coverage Determination. See Medicare covered diagnoses for Botox for the MAC-level detail.

Check the patient's actual policy: See Botox coverage by payer →

Current Botox pricing

Medicare ASP+6%: $6.514 / 1 unit · $1,009.67 / 155 units. For the 155-Unit chronic-migraine claim, the drug line prices at 155 × $6.514 = $1,009.67; add the 45-Unit JW line ($293.13, paid at the same rate) and the $156.98 non-facility PFS allowance for 64615, and the claim totals $1,459.78 before the sequester. The procedure code, and its rate, changes by indication; see the billing reference above.

Sequestration reduces Medicare's 80% share by 2%. Commercial plans pay a contracted rate that differs by payer and state.

4 doses a year (155 Units every 12 weeks) at $1,459.78 per dose — drug (including the 45-unit JW line) plus 64615 administration — total $5,839.12 before the sequester. That is the full annual drug-plus-administration cost for a patient staying on schedule, before benefits or assistance.

Look up commercial reimbursement →

Patient cost

The patient's actual responsibility depends on: payer allowed rate · remaining Part B deductible ($283 in 2026) · benefits · − assistance · = patient responsibility. At 20% coinsurance with the deductible already met, a Medicare patient's share of the 155-Unit chronic-migraine claim is roughly $291.96: $201.93 on the drug line, $58.63 on the 45-Unit JW line (Medicare pays discarded drug, and the coinsurance follows), $31.40 on the 64615 procedure line. The procedure carries its own coinsurance, separate from the drug's, and both lines change by indication.

Calculate a Botox patient estimate →

Copay & financial assistance

Two AbbVie programs cover Botox: the BOTOX Savings Program pays eligible commercial patients' drug and procedure copays, up to $4,000 a year ($1,000 per treatment and $5,000 a year for spasticity), capped at 5 treatments in any 12-month period; myAbbVie Assist provides the drug free to qualifying uninsured patients but does not cover the procedure. Neither covers Medicare, Medicaid, TRICARE or VA patients. Check current open/closed status before pointing a patient to either, since status changes without notice.

The one foundation fund on file for Botox, HealthWell’s Migraine Fund, is closed to new applications (last checked June 14, 2026) and covers chronic migraine only. See current Botox assistance programs →

See current Botox assistance programs →

Common Botox denials & fixes